-
Luspatercept, sold
under the
brand name Reblozyl, is a
medication used for the
treatment of
anemia in beta thal****emia and
myelodysplastic syndromes. The...
- supplementation, in the form of
folic acid, is
often recommended in thal****emia.
Luspatercept is a drug used to
treat anemia in
adults with β-thal****emia, it can improve...
- supplementation, in the form of
folic acid, is
often recommended in thal****emia.
Luspatercept is a drug used to
treat anemia in
adults with β-thal****emia, it can improve...
- has four
drugs in
clinical trials, and one in
preclinical development.
Luspatercept (ACE-536) for
anemia Sotatercept (ACE-011) for
pulmonary arterial hypertension...
- of MDS and the
median duration of
response is
greater than 2 years.
Luspatercept is a TGFβ
ligand that acts to
decrease SMAD2 and SMAD3
signaling involved...
-
selective list of
investigational products under development, as of 2023:
Luspatercept -
phase III: On 28
August 2023, BMS' drug
Reblozyl has
received FDA label...
- over Sotatercept, used in the
treatment of
pulmonary hypertension, and
luspatercept-aamt. In
September 2022, the
company announced it
would acquire Vence...
- myeloma.
Development of this drug was su****ded by the
development of
luspatercept (Reblozyl), a
modified activin receptor type 2B (ACTRIIB-Fc)
based ligand...
- glycol-epoetin beta B03XA04
Peginesatide B03XA05
Roxadustat B03XA06
Luspatercept B03XA07
Daprodustat B03XA08
Vadadustat B03XA09
Molidustat B03XA10 Efepoetin...
-
curative for some children.
Medications like deferoxamine,
deferiprone and
luspatercept. Gene therapy,
exagamglogene autotemcel is
approved for
medical use in...
